2011 - ISBTS 2011 Symposium


Oral Communications 16: Long Term Outcomes

21.319 - Long term results after intestinal transplantation from a single South-American Center

Presenter: Gabriel E., Gondolesi, Buenos Aires, Argentina
Authors: Gabriel Gondolesi1, Hector Solar1, Constanza Echeverría1, Juan Manuel Padín1, Fabio Nachman2, Guillermo Orce3, Adriana Crivelli1, Maria Inés Martinez1, Julio Trentadue4, Fransisco Klein5, Adriana Fernández1, Carolina Rumbo1,2


319
Long term results after intestinal transplantation from a single South-American Center

Gabriel Gondolesi1, Hector Solar1, Constanza Echeverría1, Juan Manuel Padín1, Fabio Nachman2, Guillermo Orce3, Adriana Crivelli1, Maria Inés Martinez1, Julio Trentadue4, Fransisco Klein5, Adriana Fernández1, Carolina Rumbo1,2

1Instituto de Trasplante Multiorganico, Unidad de Rehabilitación, Nutrición y Trasplante Intestinal, Hospital Universitario - Fundación Favaloro, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina; 2Servicio de Gastroenterología, Hospital Universitario - Fundación Favaloro, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina; 3Servicio de Anestesiología, Hospital Universitario - Fundación Favaloro, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina; 4Servicio de Terapia Intensiva Pediátrica, Hospital Universitario - Fundación Favaloro, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina; 5Servicio de Terapia Intensiva Adultos, Hospital Universitario - Fundación Favaloro, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

In South America, intestinal failure patients (pts) had the only option of parenteral nutrition (PN) as available treatment for many years because intestinal transplantation (ITx) used to be anecdotal.

Aim: to report the surgical and nutritional outcomes of the largest series of ITx performed at a single center.

Material and Methods: retrospective analysis of all consecutive ITx performed between May 2006 and April 2011. Diagnoses, pre ITx mean time on PN, indication for ITx, time and mortality on the waiting list (WL), type of ITx, mean total ischemia time (TIT), and warm ischemia time (WIT), immunosuppressive regimes, re-operation rate, time for PN discontinuation, nutritional outcome, 3 and 5 year actuarial patient survival are reported.

Results: 29 ITx in 19 children and 10 adults were accomplished; 22 isolated ITx (3 including colon), 7 Multiorgan (MTO) Tx (2 combined, 5 multivisceral - 1 with kidney); 7 received abdominal rectus fascia. Primary diagnoses at evaluation were: volvulus (8), Hirschprung's disease (5), intestinal ischemia (3), gastroschisis (3), others (12);79% presented with short bowel syndrome. The mean time on PN was 32.9 months (range: 8 to 215- months). The main indication for ITx was lack of central venous accesses (12) followed by PN associated liver disease (7), catheter related infectious complications (6) and others (4).The mean time on the WL was 137 days (range: 2 to 477 days); being 179,4 days for children vs 56,4 days in adults (p<0.006). Overall mortality in the WL was 9% (25% for MTO). TIT was 8:13±1:51 hs for pediatric patients and 8:06±2:19 hs for adults (p=NS). WIT for adults and children was 38±11 min and 37±12 min respectively (p=NS). Thymoglobulin-Tacrolimus-Sirolimus-Steroids were used in the MTO and in 3 isolated ITx recipients transplanted with ABO compatible mismatch grafts o high PRA. The other patients received Anti-IL2 ab-Tacrolimus-Mycophenolate-Steroids. The re-operation rate was 55%. Nutritional outcome: children: z- BMI pre Tx -0.57 ± 1.08, z- BMI post Tx -0.45 ±0.87, zH/A pre Tx -2.43 ±1.77, zH/A post Tx -2.53 ±1.31. Adults: pre Tx BMI: 21.1±4.6, current: 21.7±4.9.  Overall 3 and 5 year patient survival is 67% and 60% respectively; and 81% and 71% for Isolated ITx.

Conclusions: After 5 years of establishing a dedicated program, our results proved that ITx is currently an available option in South America. 


You must be logged in to view recordings

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi